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Abstract
Antibiotic resistance is an increasing problem in the health care system and we are in a constant race with evolving bacteria.
Biofilm-associated growth is thought to play a key role in bacterial adaptability and antibiotic resistance. We employed a
systems biology approach to identify candidate drug targets for biofilm-associated bacteria by imitating specific
microenvironments found in microbial communities associated with biofilm formation. A previously reconstructed
metabolic model of Pseudomonas aeruginosa (PA) was used to study the effect of gene deletion on bacterial growth in
planktonic and biofilm-like environmental conditions. A set of 26 genes essential in both conditions was identified.
Moreover, these genes have no homology with any human gene. While none of these genes were essential in only one of
the conditions, we found condition-dependent genes, which could be used to slow growth specifically in biofilm-associated
PA. Furthermore, we performed a double gene deletion study and obtained 17 combinations consisting of 21 different
genes, which were conditionally essential. While most of the difference in double essential gene sets could be explained by
different medium composition found in biofilm-like and planktonic conditions, we observed a clear effect of changes in
oxygen availability on the growth performance. Eight gene pairs were found to be synthetic lethal in oxygen-limited
conditions. These gene sets may serve as novel metabolic drug targets to combat particularly biofilm-associated PA. Taken
together, this study demonstrates that metabolic modeling of human pathogens can be used to identify oxygen-sensitive
drug targets and thus, that this systems biology approach represents a powerful tool to identify novel candidate antibiotic
targets.
Citation: Sigurdsson G, Fleming RMT, Heinken A, Thiele I (2012) A Systems Biology Approach to Drug Targets in Pseudomonas aeruginosa Biofilm. PLoS ONE 7(4):
e34337. doi:10.1371/journal.pone.0034337
Editor: Ping Xu, Virginia Commonwealth University, United States of America
Received July 13, 2011; Accepted March 1, 2012; Published April 16, 2012
Copyright:  2012 Sigurdsson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by a Marie Curie International Reintegration Grant awarded to IT (Nu 249261) within the 7th European Community
Framework Program. GS was funded, in part, by a student innovation grant by the Icelandic Research Fund (Rannis). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ines.thiele@gmail.com
Introduction
Pseudomonas aeruginosa (PA) is an opportunistic human pathogen
and has an extremely versatile lifestyle. PA infection is life-
threatening for immuno-compromised patients and PA is a feared
pathogen for burn centers as well as a leading cause of death in
cystic fibrosis (CF) patients [1,2,3]. PA has a large genome with
6.3 million base pairs, which encodes for 5570 genes and is rich in
quorum sensing molecules and virulence factors [3]. PA has the
ability to form a biofilm, which is thought to contribute to its
adaptability and versatile lifestyle [4]. Furthermore, PA is often
resistant to treatment and develops antibiotic resistance over time
[5].
Biofilm is a surface attached, matrix enclosed microbial
community, which is thought to play an important role in
bacterial robustness. Biofilm-associated infections are more
persistent than planktonic infections and more resistant to
antibiotic treatment [6,7]. There are three hypotheses why this
is the case. First, the extracellular polymeric substance (EPS)
secreted by bacteria in their surrounding leads to slower
penetrations of antibacterial compounds. Second, few resistant
genotypes may be in the colony and spread the resistance
throughout the biofilm and thus, maintain the infection. Third,
the idea of a dormant zone existing at the basal layer of the biofilm
has been formulated [8]. This zone has little metabolic activity
because of low nutrient supply and thus, is ‘‘dormant’’. However,
most antibiotics are dependent on bacterial replication and
metabolic activity and therefore, bacteria located in this zone
may survive antibiotic treatment. It has also been shown that
hypoxia contributes to antibiotic resistance in PA biofilm [9].
Figure 1 shows a schematic drawing of a biofilm and the nutrient
supply across the biofilm. In general, a biofilm infection is thought
to be particularly important in certain clinical settings, such as
prosthetic infections [7], in CF [10,11], burn patients [12], and in
endocarditis [8].
Biomedical questions, such as finding new drug targets, looking
for better or novel biomarkers [13], and studying the metabolism
of human diseases [14], can be addressed using systems biology
[15]. Computational models are at the core of this effort. Genome-
scale metabolic reconstructions are genomically, genetically and
biochemically structured knowledge-bases [16]. There are meta-
bolic reconstructions for an increasing number of organisms,
including many bacteria, such as the human pathogens Helicobacter
pylori [17], Staphylococcus aureus [18], and Mycobacterium tuberculosis
[19], archaea [20,21] and eukaryotes, including Homo sapiens [22]
and Mus musculus [23,24]. These metabolic reconstructions can be
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converted into computational models in order to address
biotechnological and biomedical questions using different ap-
proaches, including constraint-based modeling [25]. The basis of
constraint-based reconstruction and analysis (COBRA) has been
described elsewhere [26,27]. COBRA has allowed the analysis of
genome-scale biochemical networks in an organized and predic-
tive manner with excessive reliance on unknown model param-
eters [27]. Condition-specific, reconstruction-derived models can
be used to predict phenotypic behavior, such as growth on
different substrates and the effect of gene deletion on growth rate
(reviewed in [15,28]).
In this study, we employed the published reconstruction of
Pseudomonas aeruginosa, iMO1056 [29], which accounts for 1056
genes (19% of the genome), 893 metabolites, and 883 reactions
(1092 including exchange reactions). It captures most of PA’s
known metabolic capabilities, such as the synthesis of amino acids,
lipids, virulence factors, and the cell wall. iMO1056 was assembled
in analogy to an established reconstruction process [30].
New antibiotics are not only urgently needed for PA, but for
many major human pathogens. Metabolic drug targets are
interesting candidates for antibiotics as they offer a broad
spectrum of possibilities and are likely to be phylogenetically
conserved [18]. It is important that drug targets are essential for
the organism and not present in the host. In this study, we wanted
to test whether PA’s metabolic model (iMO1056) could be used to
suggest novel drug targets. At the same time, we were interested in
modeling some properties of the biofilm and to propose candidate
drugs particularly effective against biofilm-associated bacteria.
Generally, it would be interesting to see whether one could use a
system biology approach to design strain-dependent antibiotics.
Antibiotics, which are available today (e.g., b-lactams, tetracy-
cline’s, and cephalosporin), act on a group of bacteria, e.g., gram-
negative, gram-positive, aerobes, or anaerobes. By developing
strain-dependent antibiotics, one could avoid complications arising
from eliminating also the commensal flora. Such medication could
also lead to decreased use of broad-spectrum antibiotics, reducing
the selective pressure for widespread antibiotic resistance. It has
been suggested that multi-target therapeutics could be effective for
the same reason [31,32], which motivated us to perform a
computational double deletion to extend the list of suitable drug-
targets.
Materials and Methods
Metabolic reconstruction of PA
All simulations were done using a previously published genome-
scale metabolic reconstruction of PA, iMO1056 [29]. We
downloaded the reconstruction from the Papin laboratory website
(http://bme.virginia.edu/csbl/downloads-pseudomonas.php). To
improve the model’s consistency, we modified it as follows. First,
we removed all duplicate reactions, which had a reversible and an
irreversible version by keeping the reversible reaction (SI material,
Table S1). Subsequently, we refined the directionality of all
network reactions using thermodynamic analysis [33,34]. Reaction
bounds were only changed when the predicted in vivo standard
transformed Gibbs energy indicated a qualitatively reversible
reaction to be irreversible. The purpose of this valuation was to
remove thermodynamically infeasible loops [35]. Details on the
changed reaction directionality can be found in Table S1. Using
the resulting PA model, we calculated the essential genes for all
simulation conditions provided by Oberhardt et al. [29], i.e., we set
the bounds of all reactions associated with a particular gene to zero
and optimized the knock-out model for biomass production. The
results were compared with the ones reported by Oberhardt et al.
[29].
Simulation constraints
Using flux balance analysis (FBA) [27], we simulated two
different medium conditions: rich medium (Lucia-broth) and
minimal medium (M9 medium supplemented with glucose) as
described in Oberhardt et al. [29]. We distinguished high oxygen
conditions (high O2, vO2_lb =220 mmol.gDW
21. hr1, vO2_ub = 0
mmol.gDW
21.hr21) and microaerobic conditions (low O2, vO2_lb
=25 mmol.gDW
21.hr-1, vO2_ub = 0 mmol.gDW
21.hr21), as
reported in Thiele et al. [17]. Taken together, we simulated the
four following conditions: rich medium – high O2, rich medium –
low O2, minimal medium – high O2, and minimal medium – low
O2. All constraints are listed in Table S2.
Single gene deletion study
The effect of a single gene knock-out on the production of
individual biomass precursors was determined by adding a
demand reaction for each biomass precursor contained in the
biomass reaction in the form of ‘DM_biomass_precursor’. The
lower bound (lb) was set to 0mmol.gDW
21.hr21 and the upper
bound (ub) to 1000mmol.gDW
21.hr21 for each demand reaction.
Then, we deleted each gene in the model by setting the lower and
upper bound of the associated reaction(s) to 0 mmol.gDW
21.hr21
and maximized each biomass precursor separately. The obtained
value was stored. This procedure was repeated for all simulation
conditions. This analysis was repeated for all 1056 genes included
in the PA reconstruction. Subsequent analysis considered only
those genes that fit the following criteria i) abolished in silico growth
(i.e., growth rate was 0 hr21), ii) reported to be essential
experimentally, and iii) reported to have no homologous genes
in humans (based on Perumal et al. [36]). These criteria narrowed
our focus to a set of 398 genes.
Candidate drug targets from the single deletion study
To identify potential drug targets, we compared the prediction
of essential genes in rich medium with experimental data [37,38].
We then determined whether these in silico and in vivo essential
genes had known homologous genes in the human genome (based
on Perumal et al. [36]) as it was desirable that candidate drug
targets are unique to PA. We extended this list to include genes
that were found to be essential in minimal medium, but for which
no experimental data were available. We also compared our drug
targets with the Drugbank database (http://www.drugbank.ca/)
[39] to ensure that none of these predictions were already targeted.
Double gene deletion study
To identify synthetic lethal genes, which could serve as
candidate drug targets, we systematically deleted all combinations
of the non-essential and non-homologue genes, and determined
the in silico growth rate of the double knockout mutants by
maximizing for biomass production. We repeated this procedure
for all simulation conditions.
Software
All computational simulations with iMO1056 were performed
using MATLAB (The MathWorks Inc.). GLPK (GNU Linear
Programming Kit) was used as a linear programming solver. The
constraint-based methods for all simulations were performed in
MATLAB using the COBRA toolbox [40,41].
Systems Biology of P. aeruginosa in Biofilm
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Results
In this study, we aimed to identify candidate drug targets for
biofilm-associated bacteria using a systems biology approach. We
employed a previously published genome-scale metabolic recon-
struction of Pseudomonas aeruginosa (PA), iMO1056, to compute
single and double gene essentiality in different microenvironments
typically found in microbial communities associated with biofilm.
The results were analyzed with specific emphasis on oxygen-
sensitive mutants. The list of candidate metabolic drug targets was
reduced to only include targets without human homologues.
Simulating different environments
To study the effect of different growth environments typical for
planktonic and for biofilm-associated PA, we made the following
assumptions. The planktonic PA encounters generally nutrient-
rich and high oxygen conditions. In contrast, biofilm-associated
PAs have different microenvironments that span nutrient rich to
nutrient-poor and oxygen-rich to oxygen poor conditions
(Figure 1). We simulated these four different environmental
conditions, where nutrient rich, high oxygen corresponds to a
planktonic microenvironment and nutrient poor, low and high
oxygen, and nutrient rich, low oxygen to biofilm microenviron-
ments. We wanted to investigate pathways and genes that were
only used in biofilm growing bacteria but not in planktonic
bacteria. Therefore, we computed the corresponding growth
phenotype for wildtype PA and single knockout PA. As expected,
different essential genes were observed for rich and minimal
medium but no additional essential genes could be observed when
changing from high to low oxygen uptake (data not shown).
Candidate drug targets from the single deletion study
Based on our criteria for drug candidates, described in the
method section, we identified 41 candidate metabolic drug targets
in iMO1056. A total of 16 of these potential drug targets belonged
to the lipid and cell wall synthesis subsystems and are specific for
PA. Further 19 essential genes belonged to the amino acid
metabolism subsystem. These genes represent ideal drug targets
since they are not homologous to any human genes because they
are all a part of the indispensable amino acids in man. Finally,
there were six essential genes associated with cofactor synthesis
subsystem.
In rich medium, we identified 21 as non-essential in silico, but
which are known to be essential in vivo (false-negatives, Table 1,
Table S3). These genes have no homologous genes in the human
genome and could therefore also be potential drug targets. Many
of these genes affected the same subsystems as listed above;
however, some of the essential genes affected central metabolic
functions, such as the TCA cycle (PA1582, Sdh) and Glycolysis/
Gluconeogenesis (PA4043, Fba) (Table 1). In contrast, in rich
medium, 29 of 54 genes with no human homolog were non-
essential in vivo and can thus be considered as false-positives. In
minimal medium, the number of false-positives was 48 of 74 genes.
Oxygen dependent use of genes and pathways in PA
By comparing the different effects of single gene deletion on the
biomass precursor synthesis between normal and low O2 level, we
could identify reactions affecting the metabolism singularly due to
the oxygen level. We found 63 genes that had different effects on
the biomass precursor synthesis between normoxic rich medium
and hypoxic rich medium conditions. Of these 63 genes, 40
concerned the amino acid metabolism, 14 were in central
metabolism, and nine genes belonged to other subsystems. For
the two minimal medium growth conditions, we found 29 genes,
which showed different growth phenotypes when deleted. Ten of
them concerned the amino acid metabolism, 11 were in central
metabolism, and eight genes belonged to other subsystems. Due to
the difference in medium composition of rich and minimal
medium, there were fewer essential genes in rich medium and
subsequently, more oxygen-sensitive genes in rich medium. This
oxygen-dependency was not observed in minimal medium due to
growth essentiality of these genes. Taken together, we could
identify a core set of 28 oxygen-dependent genes in PA (Table 2).
Figure 1. Schematic representation of a biofilm. This figure shows a schematic alignment of a biofilm and how nutrition and oxygen varies
depending on the position of P. aeruginosa (PAO1) within the biofilm. From top to bottom and from the edge to the middle, the oxygen
concentration decreases. The nutrient supply is more limited at the bottom and in the middle than on the top and at the boundaries of the biofilm.
The redox potential also decreases from top to bottom. The pH value and endogenous nutrient concentrations thus vary according to the position of
PA in the biofilm. The colonies PAO1_1.1 and PAO1_1.3 have the highest oxygen and nutrient supply, while for PAO1_3.2, these factors are most
limited.
doi:10.1371/journal.pone.0034337.g001
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Table 1. This table lists all genes, which abolished PA growth in a single gene deletion and which had no homologous genes in
the human genome.
Subsystem
In silico + experimental
evidence Experimental evidence In silico evidence In silico minimal medium
Alanine biosynthesis Alr (PA4930)
Arginine, putrescine, and spermidine
metabolism
UreB (PA4867) ArgB (PA5323)
Aromatic amino acids AroC (PA1681), AroK (PA5039) AroB (PA5038), AroA
(PA3164), AroE (PA0025)
TrpA (PA0035), TrpB (PA0036),
PheA (PA3166)
Biosynthesis of cofactors, prosthetic groups
and carriers, cell wall/ Lipopolysaccharide/
capsule
UppS (PA3652)
Biotin biosynthesis AccC (PA4848)
Branched chain amino acid biosynthesis IlvC (PA4694), IlvD (PA0353)
Cell envelope biosynthesis GlmU (PA5552), GlmS (PA5549),
MurI (PA4662), MraY (PA4415),
MurE (PA4417), MurC (PA4411),
MurB (PA2977)
DdlB (PA4410), DdlA
(PA4201), MurA
(PA4450),MurD (PA4414)
Cell envelope biosynthesis- O-antigen RmlA (PA5163) RmlC (PA5164) RmlB (PA5161)
Citrate acid cycle SdhC (PA1581), SdhD
(PA1582)
Coenzyme A biosynthesis CoaE (PA4529), Dfp (PA4848) PanE (PA4397) PanB (PA4729)
PanC (PA4730)
Cysteine metabolism CysC (PA1393) CysH (PA1756)
Fatty acid biosynthesis FabB (PA1609)
Folate metabolism FolB (PA0582), FolP (PA4750) FolK (PA4728) PhoA (PA3296)
Fructose and mannose metabolism MtlZ (PA2344)
Glutamate and glutamine Biosynthesis GlnA (PA5119)
Glycine, serine, and threonine metabolism,
aminoacyl-tRNA biosynthesis
GlyQ (PA0009), GlyS (PA0008)
Glycolysis/ gluconeogenesis Fba (PA0555)
Histidine metabolism HisE (PA5067) HisG (PA4449), HisD (PA4448),
HisB (PA5143), HisI (PA5066),
HisA (PA5141)
Isoprenoid biosynthesis IspA (PA4043)
Lipopolysaccharide biosynthesis, core RfaD (PA3337)
Lipopolysaccharide biosynthesis, lipid A KdsB (PA2979,) LpxB (PA3643),
LpxK (PA2981), LpxA (PA3644)
Kds (PA4458)
Membrane lipid metabolism AccA (PA3639), AccB (PA4847),
AccD (PA3112) Psd (PA4957)
PssA (PA4693)
Methionine metabolism MetX (PA0390)
NAD biosynthesis NadD (PA4006)
Oxidative phosphorylation SdhA (PA1583), SdhB
(PA1584), LldA (PA2382)
Peptidoglycan biosynthesis BacA (PA1959)
Phenylalanine, tyrosine and tryptophan
biosynthesis
TrpF (PA3113)
Purine and pyrimidine biosynthesis PyrF (PA2876) PurH (PA4854), PurB (PA2629),
PurF (PA3108), PurM
(PA0945), PurC (PA1013)
Pyridoxine metabolism ThrC (PA3735)
Riboflavin metabolism RibD (PA4056) RibA (PA4047) RibB (PA4054)
Tetrapyrrole biosynthesis CobA (PA1778)
Thiamine metabolism ThiL (PA4051)
Threonine and lysine metabolism LysC (PA0904) Asd (PA3117) Hom (PA3736)
Ubiquinone biosynthesis UbiG (PA3171)
Vitamin B6 metabolism PdxA (PA0593)
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Effect of single gene deletions on biomass precursor
synthesis capability
To refine our analysis, we calculated the effect of single gene
deletion on the synthesis of the different biomass precursors
(Figure 2). Apart from obvious differences in gene essentiality due
to the lack of amino acids in the minimal medium, a comparison
of the different growth conditions only revealed subtle differences
between high and low O2 (Figure 2, Box A). Many of the essential
genes in minimal medium caused a reduced biomass precursor
synthesis rate in rich medium when deleted (Figure 2, Box B). We
distinguished the following three categories depending on the
effect of the gene deletion on different biomass precursors:
Case 1- local effect. 27 genes affected the production of only
single biomass precursors. For example, the deletion of PA5312
(KauB) affected only the synthesis of spermidine, PA5067 (HisE)
only affected histidine synthesis, and PA1588 (SucC) only affected
succinyl-coenzyme A synthesis under all environmental conditions
(Figure 2, arrows).
Case 2- subsystem effect. The deletion of many genes
affected the production of multiple biomass precursors, most of
which belonged to the same category of precursors (e.g., amino
acids and nucleotides). For example, the deletion of any of the
genes in Box C (Figure 2) affected the production of amino acid
precursors, which was the case for all environmental conditions.
This result shows that the gene products synthesizing amino acids
are acting very locally in the metabolic network.
Case 3 - global effect. There were seven genes, whose
deletion had a global effect on the metabolic network. They
affected the synthesis of 20 or more biomass precursors. For
example, the deletion of PA3686 (Adk) affected the synthesis of 30
precursors under all environmental conditions. PA2634 (Icl_h)
deletion had a global effect in rich media but had very little to no
effect in minimal media. PA3194 (Edd) deletion had a global effect
under all conditions but the set of precursors and the range of
effects differed between environmental conditions. For example,
the lipid precursors (Figure 2, Box D) were only affected in
minimal media, regardless of the oxygen conditions. In contrast,
deletion of PA0555 (Fba) had a global effect in rich media but
almost no effect in minimal media. These globally acting genes are
particularly interesting as drug targets since resistance may be
hampered by their broad effect on metabolism.
Double gene deletion study
Double deletion study was performed for the 230 metabolic
genes that were found to be non-essential in the single gene
deletion analysis and for which no homologous genes could be
identified in the human genome. We obtained 17 double knockout
combinations, which could abolish iMO1056’s growth, consisting
of 21 distinct genes. Interestingly, we found different sets of
combinations of essential double knockouts between the four
environmental conditions (Figure 3). To understand why these
combinations abolished iMO1056 growth and why this difference
occurred between the conditions, we investigated the metabolic
network topology. However, visual based analysis (based on
iMO1056’s metabolic map [29]) of the double knockout pairs
turned out to be difficult for identification of a direct link between
the individual pairs. While most reactions had neither clear visual
links nor obvious metabolic clues in terms of reaction content, we
could determine some metabolic relationships. For instance,
PA5312 (KauB) and PA4731 (PanD) act both on beta-alanine
(ala-B) metabolism. This metabolite was not present in the
medium and only one other intracellular reaction (encoded by
PA0132 (OapT)) was present in the reconstruction that was
involved in ala-B metabolism. Our results suggest that the
presence of only one pathway available was insufficient to sustain
growth under oxygen-limited conditions and thus, the observed
essentiality of the two genes could be explained. OapT was not
considered in the double deletion study because it did not pass the
criteria for a suitable drug target (see method section). The
essentiality of the double knockout mutant PA5206 (ArgE) and
PA4402 (ArgJ) can be explained by the fact that the reactions
catalyzed by the corresponding gene products were a part of the
same reaction chain. The deletion of these reactions abolished the
flux through almost all possible reactions in the glutamine and
These genes were sorted based on available evidence for their in vivo essentiality in literature [37,38]. The first row represents genes that were essential in silico and
have experimental data showing their essentiality. The second column lists genes that were reported to be essential experimentally but were not predicted to be
essential in the in silico analysis. The genes in last two columns had no experimental support but were found to be essential in silico.
doi:10.1371/journal.pone.0034337.t001
Table 1. Cont.
Table 2 Oxygen-sensitive genes.
Subsystem Genes
Amino acid catabolism FolD (PA1796), FdnI (P4810), FdnH (PA4811), FdnG (PA4812)
Amino acid synthesis LysC (PA0904), Hom (PA3736), Ldh (PA3418), AruH (PA4976), GdhA (PA4588)
Central metabolism Fda (PA0555), SdhC (PA1581), SdhD (PA1582), SdhA (PA1583), SdhB (PA1584), Fbp (PA5110),
TktA (PA0548), AceA (PA2634), Edd (PA3194), GapA (PA3195)
Energy metabolism PetC(PA4429), Ppa (PA4031)
Ethanol/ pyruvate metabolism Pta (PA0835)
Nucleotide synthesis Adk (PA3686), PyrB (PA0402), PyrC (PA3527), PyrF (PA2876)
Unassigned CynT (PA2053)
Vitamin and cofactor synthesis ThrC (PA3735)
This table lists all genes that were found to be oxygen-dependent in minimal and rich media conditions.
doi:10.1371/journal.pone.0034337.t002
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glutamate synthesis, and thus in minimal medium, when these
metabolites were not provided, the reactions associated to the
deleted genes became essential.
Discussion
The overall aim of this study was to determine metabolic
phenotypic differences between Pseudomonas aeruginosa (PA) under
different environmental conditions. In particular, we were
interested in identifying candidate metabolic drug targets that
reduce or abolish growth in biofilm-associated PA. Current
antibiotics are most effective against replicating, metabolically
active bacteria. In contrast, the dormant zone in a biofilm is
insensitive towards this antibiotic treatment as bacteria located in
this zone are mostly metabolically inactive. As metabolic drug
targets do not depend on replication, they have the promise to
selectively target slow growing bacteria found in biofilm. We
performed systematic in silico single gene and double gene deletion
studies to identify candidate metabolic drug targets potent to
inhibit growth of biofilm-associated PA, in particular, bacteria
growing in the lowest layer of the biofilm under hypoxic and
nutrient poor conditions.
In the single gene deletion study, we evaluated the effect of each
gene deletion on the synthesis of each precursor captured in the
biomass reaction. This was done to increase the resolution of the
single gene deletion. We were hoping to find genes that affected
different precursor synthesis in the four different environments,
especially, between the fast growing planktonic bacteria and the
dormant zone of the biofilm. One may expect that slow growing
bacteria in the dormant zone would maintain vital cellular
functions, while omitting costly biosynthetic processes. We
detected a few soft phenotypes with condition specific effect in
hypoxic or nutrient poor media but, in general, we did not observe
much growth difference of single deletion mutants between the
simulated growth conditions. In fact, no single knockout disrupted
growth singularly under hypoxic conditions. The single gene
deletion analysis identified 41 potential drug targets for all four
conditions. Moreover, 26 of the potential drug targets have been
shown to abolish growth in vivo [37,38] and thus, confirmed our in
silico predictions under rich medium conditions. The remaining 15
drug targets were predict to be essential in minimal media and
therefore may be of special interest for biofilm-associated bacteria.
Recently, Pommerenke et al. performed a genome-wide
transposon mutant study of the P. aeruginosa strain A14 (4030
mutants in total) [42]. They determined a network of phenotypic
relatedness between these mutants. Six genes predicted to be
essential in our single gene deletion study (AccC, GlmU, Alr, AroB,
NadD, and RibB) and three genes that were essential in our double
knockout study (Edd, ArgJ, and SucC) were included in the global
phenotypic network. The neighbors of these genes in the phenotypic
Figure 2. Essential genes for biomass precursor synthesis. This figure shows the results of the single gene deletion study, where the 398
candidate drug target genes are listed along the y-axis and the biomass precursors found in the biomass reaction [29] are listed on the x-axis. The
color scale shows biomass precursor synthesis ability with zero corresponding to a complete loss of the precursor synthesis capability. Interesting
areas in the four plots are highlighted with red boxes and discussed further in the text. Box A shows genes, which were essential in minimal but not in
rich media. Box B corresponds to the area of amino acid precursors. We can see that in rich media the gene deletion had an effect on amino acid
precursors but was not essential compared to minimal media, in which the gene deletion was essential. Box C highlights genes with subsystem effect.
Box D shows those genes, which have a global effect but differed between minimal and rich media conditions. Box E shows similar tendency but a
global effect is only observed in rich media conditions while gene deletion had a moderate effect in minimal media conditions. The arrows point to i)
some few examples of single effect of gene deletion or ii) genes, whose deletion affected only a single precursor.
doi:10.1371/journal.pone.0034337.g002
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landscape may be useful targets for identifying further candidate
drug targets experimentally. Furthermore, Mu¨sken et al. screened a
set of transposon mutants for their ability to form biofilm [43]. They
also identified genetic determinants promoting survival under
microaerophilic conditions, which were essential for P. aeruginosa
biofilm establishment. In total, 394mutants were deficient in biofilm
formation. Genes involved in arginine metabolism were particularly
affected indicating that a functional arginine metabolism is essential
for biofilm formation. Several genes involved in arginine biosyn-
thesis as well as arginine and ornithine degradation caused reduced
biofilm formation in the respective mutants. Although the genes
identified in this mutant study were not found to be essential in our
in silico analysis, we predicted another gene involved in arginine
metabolism (ArgB) to be essential on minimal medium. Further-
more, we predicted a double knockout mutant of ArgE and ArgJ,
whose gene products are involved in ornithine and arginine
biosynthesis, to be nonviable on minimal medium (Figure 3). Thus,
our in silico results also suggest an importance of arginine
metabolism for biofilm formation and underline the value of a
systems biology approach to identify candidate drug targets.
Ten genes, predicted to be essential in our single gene deletion
study, also caused poor biofilm formation in vivo, when deleted
[43]. The reason for the low number of matches is most probably
that Mu¨sken et al. targeted a different objective: the ability of PA to
form biofilm rather than viability, although these two factors are
probably correlated. Furthermore, the analysis was performed for
the strain PA14 instead of PAO1. Six among the ten overlapping
genes (AroB, AroC, PanB, PanC, IlvC, and TrpD), belonging to
the subsystems of aromatic amino acid metabolism, branched
chain amino acid biosynthesis, and coenzyme A biosynthesis, have
no homolog in humans and are thus potential drug targets. The
experimental observation that mutations in these genes cause
deficiency in biofilm formation supports our in silico prediction that
their gene products are indeed metabolic weak points of PA.
We performed a double gene deletion study to extend our
candidate drug target list. Essential double knockout combinations are
very difficult to predict solely based on reaction maps and biochemical
knowledge; thus, they are ideal for a network-based analysis. Using the
PA in silico model, we aimed to predict novel metabolic targets that
could be followed up by experimental work. Considering the high
number of possible double knockout mutants, computational
approaches are needed to optimize experimental work and to increase
the success rate, i.e., finding synthetic lethal mutants. The double
deletion of non-essential genes with no homologous genes in the
human genome resulted in a promising set of candidate drug targets.
Two genes involved in pyrimidine metabolism (PyrB and PyrC) were
predicted to be lethal in double knockouts involving AlgC (Figure 3).
The deletion of both genes caused poor biofilm formation in the
respective mutants in vivo [43] underlining that they may be indeed
potential drug targets. Furthermore, we identified gene pairs predicted
to be lethal in double deletion, which were hypoxic-sensitive (Figure 3).
Pairing non-essential genes for multi-target drug medication could
extend current treatment options greatly and may turn out to be more
effective against PA than single drug target options. It has been also
hypothesized that multi-targeting is less likely to induce antibiotic
resistance [31]. As testing of all possible double knockout combinations
may become experimentally intractable, the metabolic modeling of
PA be a powerful approach to identify a testable subset. However,
more systematic analysis and further studies combining experimental
work and computational predictions will be necessary to refine the set
of proposed candidate lethal double gene deletions under hypoxic
conditions. If the numbers of possible pairs (52.900) and of in silico
essential pairs (17) are considered, it is evident that the prediction of
pairs to be investigated experimentally when relying solely on
biochemistry and reaction maps would be extremely challenging.
The use of metabolic modeling for prediction of candidate drug
targets is a growing research area in systems biology. For instance,
iMO1056 has been used to propose 41 candidate drug targets for PA
[44]. Furthermore, a metabolic network of Burkholderia cenocepacia has
Figure 3. Synthetic essential genes. This figure shows the results of the double gene deletion study. White background corresponds to rich
media and gray to minimal media. The diagram in the left hand side compare oxygen rich and the right hand side compares oxygen poor conditions.
Red cells indicate essential double knockout combinations.
doi:10.1371/journal.pone.0034337.g003
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been reconstructed and drug targets have been proposed for this
pathogen, which also infects cystic fibrosis patients [45]. Recently,
Oberhardt et al. integrated microarray data from PA growing in the
lung epithelium of a cystic fibrosis patient with iMO1056 [46]. The
microarray data measured gene expression level at different time
points to observe the adaptation of PA in a CF lung [46]. The authors
also performed a single gene deletion study while simulating growth
of PA under microaerobic conditions. The deletion of 54 genes with
no homology to human genes has been predicted to be lethal on in
silico synthetic cystic fibrosis medium [46]. Of those, 51 overlapped
with genes predicted to be essential both on minimal medium and
rich medium in our study. The three remaining genes (PyrB, PyrC,
and PyrF) were predicted to be lethal in a double knockout with AlgC
in our study. It is likely that these genes were nonlethal in our single
gene deletion study due to differences in the simulated medium
composition and constraints compared to the study setup by
Oberhardt et al. Interestingly, the effect of gene deletion on growth
rates changed when different isolate-specific models, representing PA
infection at different time points, were simulated [46]. Their
predictions of infection stage-specific drug targets, taken together
with our predictions of drug targets specific for biofilm-grown PA,
should be useful for designing drugs aiming for PA’s metabolic
weaknesses. It is expected that, as more data becomes available, the
PA metabolic reconstruction will be improved further, which will
ultimately improve the accuracy of the predictions. Experimental
studies testing some of the predicted hypotheses will also lead to
further refinement of the reconstruction content.
The presented work illustrates a systems biology approach to
identify candidate metabolic drug targets that consider specific
microenvironments found in biofilm. It shows that FBA can be
used to determine key metabolic differences between planktonic
and biofilm colonies and that this knowledge may be used to
propose novel drug targets.
Supporting Information
Table S1 This table lists reactions that were modified
in iMO1056.
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Table S3 This table lists genes that were essential in the
silico single gene deletion study on rich medium and on
minimal. Genes that were experimentally demonstrated to be
essential are shown for comparison. Furthermore, PA genes that
have no human homolog are listed.
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